Jared Kaltwasser

Treatment options for patients with small cell lung cancer (SCLC) who survive to a third line of therapy are insufficient, authors of a new study argue.

Glucagon-like peptide 1 receptor agonists improved disease activity, body weight, and cholesterol in patients with rheumatoid arthritis.

Questions remain related to which patients with diffuse large B-cell lymphoma (DLBCL) benefit most from radiotherapy and at what dose.

LAG-3 expression appears to be significantly elevated in patients with small cell lung cancer (SCLC).

Atomic force microscopy successfully identified nanomechanical changes in fibrotic lung tissue.

A Mendelian randomization study suggests Actinomyces plays a role in idiopathic pulmonary fibrosis, mediated by circulating inflammatory proteins.

Nanopore sequencing of chronic lymphocytic leukemia (CLL) may be a particularly good fit in under-resourced areas due to its lower cost and smaller laboratory footprint.

Early research has identified several antigens that could help facilitate the use of chimeric antigen receptor T cells in small cell lung cancer.

New treatment options are needed for patients with accelerated-phase or blast-phase myeloproliferative neoplasms (MPNs) ineligible for standard care.

Biomarkers like neutrophil-to-lymphocyte ratio could help predict treatment response to immune checkpoint inhibitors in certain patients with soft tissue sarcoma.

A wearable cough monitor generated clinically useful cough data, but patients only wore the device about half of the days of the study period.

Patients with immunoglobulin M-type monoclonal gammopathy did not experience a survival benefit from targeted therapies, a study found.

Second primary malignancies in patients with small cell lung cancer are often misdiagnosed as distant metastases.

High-risk patients who cannot find a matched sibling or matched unrelated donor may achieve a similar benefit from a haploidentical donor.

Patients with essential thrombocythemia live with a risk of developing serious bleeding complications, a new study explains.

A case series suggests using minimal residual disease to trigger anti-CD20 therapy for chronic lymphocytic leukemia (CLL) can add years to some patients’ lives.

A new report identified 11 additional high-frequency mutations in small-cell lung cancer.

Only a fraction of countries in the world have designated chronic kidney disease as a health priority.

Patients with progressive pulmonary fibrosis had longer survival with antifibrotic therapy, but only if they met a key criteria.

Patients with acute exacerbations of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis face steep odds and benefit from palliative care.

Patients who underwent neoadjuvant radiotherapy for soft tissue sarcoma (STS) spent longer in the hospital and were more likely to have wound complications.

Super-enhancer-related microRNAs (miRNAs) reveal diverse subtypes of small cell lung cancer (SCLC), offering potential as diagnostic and prognostic biomarkers.

Among patients with hematologic malignancies who were diagnosed with COVID-19, about one-quarter experienced critical illness, and most of those patients died.

Polyethylene terephthalate microplastics are the most common microplastics encountered in daily life, and there are several reasons why they may play a role in lung diseases like idiopathic pulmonary fibrosis.

Psoriasis received the second-most funding of any pediatric dermatology condition, even though it ranked fifth in terms of disease burden.

Patients with small cell lung cancer (SCLC) experienced better responses to immune checkpoint inhibitors if they had higher levels of NOTCH1 expression in a recent study.

The findings could help clinicians individualize infection-prevention strategies in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

The findings may inform future studies on the therapeutic strategy for patients with small cell lung cancer (SCLC).

The 6-month progression-free survival rate for the combination therapy was 52.2%.

A single-center study comparing patients with chronic lymphocytic leukemia receiving venetoclax as part of a clinical trial and patients receiving it in routine clinical practice showed very high complete response rates in both groups.